Carboplatin

Findings presented at ASCO Quality Care Symposium provided new insights into the effects last year’s cisplatin shortage had on patients with head and neck cancer.

Two common platinum-based chemotherapies that had been in short supply for most of the past year are much more widely available this summer, according to results of a new National Comprehensive Cancer Network survey.

In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

Cancer centers in the United States continue to experience critical shortages of commonly used platinum-based chemotherapies, according to survey results from National Comprehensive Cancer Network.

Glasgow prognostic score appeared associated with survival among patients with small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide, according to study results.

The use of low-intensity pulsed ultrasound with concomitant administration of IV microbubbles can improve the delivery of albumin-bound paclitaxel and carboplatin through the blood-brain barrier, study results showed.

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

SAN ANTONIO — The addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy significantly improved outcomes among patients with triple-negative breast cancer, according to study results.

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.